Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
T cells express diverse antigen-specific receptors and are required for eradicating pathogens and transformed cells. T cells expressing CD4 acquire helper effector functions and those expressing CD8 exert cytotoxic activity after antigen recognition. The protein-tyrosine phosphatase, receptor type kappa (PTPRKappa) is mutated in LEC rats, resulting in impaired CD4(+) T cell development in the thymus. However, the molecular mechanism of
PTPRK
controlling CD4(+) T cell development remains unclear. We demonstrate herein that inhibition of
PTPRK
by transducing a dominant negative form of the intracellular domain of
PTPRK
(PTPRK-ICD-DN) in bone marrow-derived stem cells suppresses the development of CD4(+) T cells. The inhibition of
PTPRK
by
PTPRK
-ICD-DN or short-hairpin RNA for
PTPRK
attenuates ERK1/2 phosphorylation in T cells after PMA and ionomycin stimulation. Total thymocytes from LEC rats also showed weaker phosphorylation of ERK1/2 after PMA and ionomycin stimulation than control thymocytes. Furthermore, inhibition of
PTPRK
by
PTPRK
-ICD-DN suppressed
MEK1
/2 and c-Raf phosphorylation, which is required for ERK1/2 phosphorylation. These data indicate that PPTRK positively regulates ERK1/2 phosphorylation, which impacts CD4(+) T cell development.
...
PMID:Protein-tyrosine phosphatase-kappa regulates CD4+ T cell development through ERK1/2-mediated signaling. 1980 Mar 17